Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer

2007 ◽  
Vol 251 (1) ◽  
pp. 164-167 ◽  
Author(s):  
Hidekatsu Nakai ◽  
Yoh Watanabe ◽  
Haruhiko Ueda ◽  
Hiroshi Hoshiai
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Hypoxia Inducible Factor ◽  
Hypoxia Inducible Factor 1 ◽  
Primary Epithelial Ovarian Cancer ◽  
Platinum Chemotherapy

Central Nervous System Metastases from Primary Epithelial Ovarian Cancer

2003 ◽  
Vol 10 (3) ◽  
pp. 244-253 ◽  
Author(s):  
Lalit Kumar ◽  
Suchitra Barge ◽  
Ashok K. Mahapatra ◽  
Sanjay Thulkar ◽  
Gaura Kishore Rath ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Epithelial Ovarian Cancer ◽  
Central Nervous System Metastases ◽  
Primary Epithelial Ovarian Cancer

scholarly journals Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)

2020 ◽  
Vol 30 (4) ◽  
pp. 509-514
Author(s):  
Irena Rohr ◽  
Sara Alavi ◽  
Rolf Richter ◽  
Maren Keller ◽  
Radoslav Chekerov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Adverse Effects ◽  
Maintenance Therapy ◽  
Oral Administration ◽  
Epithelial Ovarian Cancer ◽  
Recurrent Disease ◽  
The Internet ◽  
Primary Epithelial Ovarian Cancer

BackgroundMaintenance therapy induces remission and prolongs disease free interval in primary and recurrent ovarian disease. For the treatment decision making process, aspects of quality of life and patients′ preferences are crucial, despite the fact that scientific data are lacking. Therefore, we conducted this European-wide study in patients with ovarian cancer.MethodsA 25 item questionnaire was provided to ovarian cancer patients via the internet or as a paper version in 10 European countries (Austria, Belgium, France, Germany, Italy, Romania, Slovenia, Finland, Turkey, and Spain). Data recorded were demographics, tumor stage, therapy after firstline and recurrent disease, preferences for administration, and expectations concerning maintenance therapy.ResultsOverall, 1954 patients participated from September 2013 to March 2016; 42% had recurrent disease. Most patients (98%) with primary epithelial ovarian cancer underwent surgery followed by chemotherapy (91%). Almost one-third of participants (29%) were receiving maintenance therapy whereas 45% had only heard of it. For 70% of patients with primary epithelial ovarian cancer, they heard about maintenance therapy from their doctor, 10% heard about maintenance therapy from other patients, and 8% from the internet. The main source of information about maintenance therapy in patients with epithelial ovarian cancer relapse was from the treating physician (72%), from other patients (8%), and from the internet (7%). For patients undergoing maintenance therapy, the four most disturbing adverse effects were polyneuropathy (37%), nausea (36%), hair loss (34%), and vomiting (34%). The main objective of maintenance treatment, as perceived by patients, was to increase the chances of cure (73%), improvement in quality of life (47%), and delay in tumor growth (37%). Many patients were willing to undergo maintenance therapy until tumor progression (38%) and 39% would prefer oral administration. No significant differences were detected in the cross country subanalysis regarding expectations of maintenance therapy and patients with primary or relapsed ovarian cancer.ConclusionPatients with ovarian cancer were willing to accept maintenance therapy of prolonged duration and preferred oral administration. There is still a gap between the efficacy of maintenance therapy and patient expectations. Patients need more information on the adverse effects and treatment goals of maintenance therapy to avoid misunderstandings.

Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer

2016 ◽  
Vol 26 (4) ◽  
pp. 626-631 ◽  
Author(s):  
Michelle M. Boisen ◽  
Jamie L. Lesnock ◽  
Scott D. Richard ◽  
Sushil Beriwal ◽  
Joseph L. Kelley ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Primary Response ◽  
Published Data ◽  
Second Line ◽  
First Recurrence ◽  
Oncology Practice ◽  
Platinum Chemotherapy

ObjectiveOnly 3% of patients with epithelial ovarian cancer (EOC) have a longer treatment-free interval (TFI) after second-line intravenous (IV) platinum chemotherapy than with frontline IV therapy. We sought to examine what impact second-line combination IV/intraperitoneal (IV/IP) platinum therapy might have on the ratio of second-line to first-line TFI in patients treated with second-line IP platinum chemotherapy for first recurrence after front-line IV therapy.MethodsA retrospective analysis of women who received combination platinum-based IV/IP chemotherapy for recurrent EOC between January 2005 and March 2011 was conducted. Patients were identified from the tumor registry, and office records from a large gynecologic oncology practice and patient records were reviewed. The first and second TFIs were defined as the time from the end of previous platinum-based therapy to the start of next therapy.ResultsTwenty-five women received IV/IP chemotherapy for their first EOC recurrence after IV chemotherapy. In 10 patients (40%), we observed a longer TFI after IV/IP chemotherapy than after primary IV chemotherapy. For these 10 patients, the median TFI for primary response was 22 months (range, 15–28), whereas median TFI after IV/IP chemotherapy for recurrent disease was 37 months (range, 12–61).ConclusionsFor EOC patients with limited peritoneal recurrence, 40% of patients had a second-line IP-platinum TFI that exceeded their frontline IV-platinum TFI compared to published data. These data support the use of IV/IP chemotherapy as a treatment for recurrence.

Sign in / Sign up

Export Citation Format

Share Document